Aktis Oncology, Inc.
NASDAQAktis Oncology enters the back half of August with two bellwether initiations landing on the same morning, a borrow market that has gone from tight to very loose over six weeks, and a cluster of insider sales from the prior month that still sits unresolved in the backdrop. The Street angle is the clearest lead this week. Wedbush and BMO Capital both initiated coverage on…
AKTS cost to borrow surges to 3.14%, up 154% in one week, as availability rises to 136%.
Snapshot as of 21 Aug 2026
Aktis Oncology enters the back half of August with two bellwether initiations landing on the same morning, a borrow market that has gone from tight to very loose over six weeks, and a cluster of insider sales from the…
Aktis Oncology reaches its May 22 earnings date with the short-seller dynamic that had been easing now quietly reversing. The shift is modest but directionally clear. Short interest has climbed roughly 9% over the past…
Aktis Oncology heads into its May 15 results with a notable split: fresh institutional conviction sits alongside a short-score that remains elevated even as shorts trim positions. The lending market tells a more…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AKTS — free to start on ORTEX.
Sign up for free →Open AKTS on ORTEX